Catalog Product Name CAS Number
BADC-00723 N-Acetyl-Calicheamicin 108212-76-6
N-Acetyl-Calicheamicin is a potent enediyne antitumor antibiotic that could be a potential cytotoxic DNA-binding agent in antibody-drug-conjugation (ADC). Calicheamicin is a naturally occurring hydrop... Inquiry
BADC-00337 Seco-Duocarmycin TM 1142188-60-0
Seco-Duocarmycin TM is a cytotoxic agent, used as the cytotoxic component in antibody-drug conjugates. Inquiry
BADC-00342 Seco-Duocarmycin MA 1613286-57-9
Seco-Duocarmycin MA is a cytotoxic agent, used as the cytotoxic component in antibody-drug conjugates. Inquiry
BADC-00341 Seco-Duocarmycin SA 152785-82-5
Seco-Duocarmycin SA is a cytotoxic agent, used as the cytotoxic component in antibody-drug conjugates. Inquiry
BADC-00340 PBD dimer 1222490-34-7
PBD dimer is a cytotoxic agent, used as the cytotoxic component in antibody-drug conjugates. Inquiry
BADC-00681 DC0-NH2 615538-51-7
DC0-NH2 is an effector moiety for ADC and a simplified analog of DC1 with better stability. DC0-NH2 is about 1000-fold more cytotoxic than commonly used anticancer drugs (ex. Doxorubicin). DC0-NH2 can... Inquiry
BADC-00835 DC4SMe 615538-47-1
DC4SMe is a phosphate prodrug of the cytotoxic DNA alkylating agent DC4 and can be used in the synthesis of antibody-drug conjugates (ADC) for targeted therapy of tumors. Inquiry
BADC-00680 DC1-SMe 501666-85-9
DC1-Sme, a DC1 derivative, exhibits IC50 values of 22 pM, 10 pM, 32 pM and 250 pM for Ramos, Namalwa, HL60/s and COLO 205 cancer cells, respectively. DC1, a simplified analogue of CC-1065, is an antib... Inquiry
BADC-00827 Py-MPB-amino-C3-PBD 2412924-07-1
Py-MPB-amino-C3-PBD is a cytotoxic agent comprised non-alkylating group, with antimicrobial activity. Inquiry
BADC-00826 Aniline-MPB-amino-C3-PBD 2412923-79-4
Aniline-MPB-amino-C3-PBD is a cytotoxic agent comprised of the non-alkylating group. It is a sequence-selective DNA minor-groove binding agent. Inquiry
BADC-00825 SJG-136 232931-57-6
SJG-136 is a DNA cross-linking agent, with an XL50 of 45 nM for pBR322 DNA. SJG-136 has potent antitumor activity. Inquiry
BADC-00605 Duocarmycin TM 157922-77-5
Duocarmycin TM is an exceptionally potent antitumor antibiotic. Duocarmycin TM is a DNA alkylator. Inquiry
BADC-00814 DC44SMe 1354787-76-0
DC44SMe is a phosphate prodrug of DC44 and can be used in the synthesis of antibody-drug conjugates (ADC) for the targeted treatment of cancer.. Inquiry
BADC-00588 DC41-SMe 1354787-71-5
DC41SMe, a DC1 derivative, shows cytotoxicity in Ramos, Namalwa, and HL60/s cells with IC50s ranging from 18-25 pM. DC1, a simplified analogue of CC-1065, is an antibody conjugate of cytotoxic DNA alk... Inquiry
BADC-00813 Duocarmycin SA 130288-24-3
Duocarmycin SA is a potent antitumor antibiotic with an IC50 of 10 pM. Duocarmycin SA is an extremely potent cytotoxic agent capable of inducing a sequence-selective alkylation of duplex DNA. Duocarmy... Inquiry
BADC-00223 Duocarmycin A 118292-34-5
It is produced by the strain of (Pyridamycin) Streptomyces sp. DO-88. It has strong antibacterial and antitumor activity. It can inhibit gram-positive bacteria such as Staphylococcus aureus and Strept... Inquiry
BADC-00808 Sandramycin 100940-65-6
Sandramycin ia a cyclic depsipeptide antibiotic isolated from cultured broth of a Nocardioides sp. Sandramycin is also a DNA intercalator that potently binds DNA and is an ADC cytotoxin. Sandramycin i... Inquiry

As a leading supplier for ADC cytotoxin discovery and manufacture, BOC Sciences provides a wide range of specific products that induce DNA damage to support your research.

The primarily cytotoxicity of DNA damage is manifested as inhibitory on vital cellular processes, such as transcription and replication. The anticancer activities of various chemotherapeutic agents rely on the cytotoxic consequences of DNA damage. Some tumor cells may acquire DNA repair defects during carcinogenesis because the loss of DNA surveillance contributes to hypermutable phenotype and drives early tumor development. Thus, tumor-specific defects in DDR present a unique opportunity for cancer-specific therapies. However, most cancer cells would be expected to have proficient DNA repair pathways. Therefore, therapeutic targeting specific components of DNA repair pathways in cancer cells require treatment efficacy enhancement.

DNA Anal. Chem. 2011, 83, 9, 3248–3251.

DNA Characteristics

As a biological macromolecule, DNA (deoxyribonucleic acid) composed genetic instructions to guide biological development and life functions. The main function of DNA is information storage, which can be compared to a “blueprint” or “recipe”. DNA damages apply permenant effect to DNA nucleotide sequence which occurs during the replication process and modifies genetic characteristics. DNA damge not only disrupts the nucleic acid architecture, but also leads to the killing of cancer cells through apoptosis. Biologically, various mutagens could induce DNA damages, including oxidants, alkylating agents, and high-frequency electromagnetic radiation including ultraviolet rays and X-rays. The most important DNA damage response pathways components were seen as potential cancer therapeutic targets, and numerous chemical inhibitors were designed and synthesized to target this pathway's protein. Proteins and pathways involved in with DNA damage response were catagoried into four functional groups: DNA repair, DNA repair accessory functions, DNA damage signaling, and cell survival. Novel drug development targeting DNA damage response is an active field of research and considerable interest to pharmaceutical companies.

DNA Inhibitor

DNA-binding cytotoxins exert cytotoxic effects by binding to DNA in the double helix groove. Calicheamicins, Duocarmycins, Camptothecins and Pyrrolobenzodiazepines (PBD) represent these cytotoxic drugs, all of which exhibit potent activity. These small molecules tend to bind to the minor grooves of DNA and promote alkylation, cleavage, or cross-linking strands. N-acetyl-γ-calicheamicin is commonly used as a DNA damaging agent in ADC structure for Gemtuzumabozogamicin and Inotuzumabozogamicin. It is worth noting that, due to strong hydrophobicity of Calicheamicin, each monoclonal antibody can only couple a few molecules in order to avoid aggregation of proteins.


  1. Ljungman, M.; Targeting the DNA Damage Response in Cancer. Chem. Rev., 2009, 109: 2929-2950.
  2. Anderson, M.G.; et al. ABBV-176, a PRLR antibody drug conjugate with a potent DNA-damaging PBD cytotoxin and enhanced activity with PARP inhibition. BMC Cancer., 2021, 618(21).
* Only for research. Not suitable for any diagnostic or therapeutic use.

Send Inquiry

Verification code
Inquiry Basket